AVITA Medical(US:RCEL) Globenewswireยท2025-10-09 16:49Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Avita Medical, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1]. Investigation Details - The investigation is focused on whether Avita has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [2]. Financial Performance - On August 7, 2025, Avita reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of the year. The backlog was attributed to delays in pricing determinations by contractors from the Centers for Medicare & Medicaid Services [6]. - The accumulation of unpaid claims led to uncertainty among providers, resulting in a reduction of Recell utilization during the first half of 2025 [6]. - Following the announcement of these issues, Avita's stock price fell by $1.13, or approximately 21%, from $5.38 to $4.25 per share [6].